Efficacy

Large trials of galantamine have shown clinically meaningful improvements in treated versus placebo groups:

• four point improvement in ADAS-cog score vs placebo at 6 months
• significant benefit from treatment at 12 months

Improvements are also seen in behaviour and activities of daily living.

Reference:

• 1) Wilcock, GK, Lilienfeld, S, Gaens, E. (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ, 321, 1445.